Publications by authors named "James Sweet-Jones"

Therapeutic monoclonal antibodies (mAbs) are a successful class of biologic drugs that are frequently selected from phage display libraries and transgenic mice that produce fully human antibodies. However, binding affinity to the correct epitope is necessary, but not sufficient, for a mAb to have therapeutic potential. Sequence and structural features affect the developability of an antibody, which influences its ability to be produced at scale and enter trials, or can cause late-stage failures.

View Article and Find Full Text PDF

As interest in antibody-based drug development continues to increase, the biopharmaceutical industry has begun to focus on complex multi-specific antibodies (MsAbs) as an up-and-coming class of biologic that differ from natural monoclonal antibodies through their ability to bind to more than one type of antigen. As techniques to generate such molecules have diversified, so have their formats and the need for standard notation. Previous efforts to develop a notation language for macromolecule drugs have been insufficient, or too complex, for MsAbs.

View Article and Find Full Text PDF
Article Synopsis
  • - Advances in genetic tools are now allowing researchers to study Welsh mountain sheep breeds, previously overlooked for their poor wool and meat quality, to better understand their adaptation to harsh upland environments.
  • - Genetic analyses revealed strong selection in specific genes related to local adaptation in both upland and lowland breeds, indicating differences in traits such as metabolism, cell stress responses, and color.
  • - The findings highlight new genetic variants that could enhance breeding strategies for sheep, potentially improving their adaptability and productivity across various environments.
View Article and Find Full Text PDF